MI-EATON
Intelligent power management company Eaton today announced it is displaying its growing portfolio of aftermarket low-voltage solutions for the electrified vehicle (EV) market in Europe, Middle East, and Africa (EMEA) at Automechanika Frankfurt, Sept. 10-14, in Booth #D11, Hall 3.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903236727/en/
Eaton’s OMNEX Trusted Wireless™ controllers can remotely operate heavy machinery, such as vacuum trucks, tow trucks, concrete mixers and cranes. (Photo: Business Wire)
“We are excited to expand our aftermarket portfolio in EMEA with the addition of our suite of power connections, power protection and low-voltage technologies to serve a wide range of electrified vehicles,” said Tim Bauer, vice president, Aftermarket, Eaton’s Mobility Group. “Electrified vehicle growth in the region is outpacing most other global regions, so we see a great opportunity to supply our customers with the wide product range and solutions they need.”
DC/DC converter for stepping down voltage to power accessories
Eaton’s DC/DC converter takes power from a 48-volt system and converts it to 24 volts. The bi-directional unit then converts it further to 12 volts for use in low-voltage systems. This equalizer function, in conjunction with the 12-volt battery or a split 24-volt battery system, ensures essential equipment—including antilock brakes and power steering—works in case of a power failure.
Eaton’s eyelets - lightweight and resistant to severe vibrations
Eaton’s eyelets offer hundreds of configurations to support vehicles operating in the EMEA market and elsewhere around the world. The eyelets are composed of high-grade materials to make them lightweight, more resistant to severe vibration, and able to deliver a long component service life that meets or exceeds customer requirements.
Stamped battery terminals
Eaton’s stamped battery terminals provide several benefits, including greater energy cycling performance compared to diecast or forged terminals and weight savings in many applications. The stamped battery terminals are customizable and compatible to SAE, DIN, IEC and JIS battery post configurations.
Eaton’s Bussmann series EVK fuses optimized for high-powered electrified vehicles
Eaton’s Bussmann® series EVK fuses feature ratings of up to 1,000 volts of direct current (VDC) and up to 600 amps, enabling them to meet the requirements for use in new high-powered EVs.
Eaton's hybrid and EV fuses are designed to manage and protect the charging systems of electric commercial, passenger and high-performance vehicles such as sports cars and large sport-utility vehicles.
mVEC high power circuit management
The multiplexed Vehicle Electrical Center (mVEC) offers economical CAN Network oversight for high-power circuits in vehicle power distribution. The mVEC, rated at 200 amps, can be configured to provide various OEM circuit protection and switching functions, using industry standard fuses, relays and breakers, with the status and control of each circuit accessible through J1939 CAN open messages.
OMNEX remote controls ideal for harsh environments
Eaton’s OMNEX Trusted Wireless™ remote control products have been used to wirelessly control high value machinery in harsh environments, including mining, construction, agriculture, locomotive and marine markets, with utmost reliability, precision and durability.
Learn more about Eaton’s aftermarket solutions.
Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace, and mobility markets. We are guided by our commitment to do business right, to operate sustainably, and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy sources, helping to solve the world’s most urgent power management challenges, and building a more sustainable society for people today and generations to come.
Eaton was founded in 1911 and has been listed on the New York Stock Exchange for more than a century. We reported revenues of $23.2 billion in 2023 and serve customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903236727/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TRU Simulation’s Bell 525 Flight Simulator Receives FAA Interim Level C Qualification17.11.2025 09:00:00 CET | Press release
TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Textron Aviation Inc. and Bell Textron Inc. today announced its Bell 525 Full Flight Simulator (FFS) located at the Bell Training Academy received Interim Level C qualification from the Federal Aviation Administration (FAA). Bell Textron Inc. has designed and will manufacture the Bell 525 helicopter. By achieving this milestone, pilots can earn more flight hours on the Bell 525 platform ahead of the rotorcraft’s expected FAA type certification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117520706/en/ TRU Simulation’s Bell 525 Flight Simulator receives FAA Interim Level C qualification “The accuracy and realism of our Flight Simulation Devices play a crucial role in ensuring that pilots can effectively translate their training into real-world scenarios,” said Jerry Messaris, vice president and general manager, TRU Simulation. “This q
Polpharma Biologics Confirms U.S. Launch of Tyruko® (natalizumab), the First and Only Biosimilar for Multiple Sclerosis17.11.2025 08:52:00 CET | Press release
Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now available to patients in the United States. Tyruko® is the first and only FDA-approved biosimilar of natalizumab for the treatment of relapsing forms of multiple sclerosis (MS), and also for adult patients with moderately to severely active Crohn’s disease1. Tyruko® was developed by Polpharma Biologics and will be commercialized in the U.S. by its collaboration partner Sandoz, under an exclusive global license agreement. The launch marks a significant milestone in expanding access to high-quality, affordable treatment options for patients living with MS and Crohn’s disease in the United States. Emmanuelle Lepine, Chair of the Supervisory Board, Polpharma Biologics, commented: "The U.S. launch of Tyruko® marks a pivotal moment not only for Polpharma Biologics, but for patients across the United States. This milestone r
Lone Star Acquires Multi-Asset Real Estate Portfolio from St. James’s Place17.11.2025 08:01:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Real Estate Fund VII, L.P. has successfully completed the acquisition of a multi-asset real estate portfolio from St. James’s Place (SJP) and its Property Unit Trust and Life and Pensions Trust. SJP was advised by Invesco Real Estate, the global real estate investment manager, on the sale of the portfolio. The portfolio comprises 16 high-quality assets across the UK, including multi-let industrial (“MLI”), retail, and office properties. The largest component is the MLI portfolio, which consists of 10 separate property assets predominantly located in Greater London and South East England, and offering access to major transportation and industrial hubs — making them highly attractive for last-mile delivery and regional distribution. The office properties are all situated in London, while the retail assets consist of high-quality retail warehouses with strong tenant bases. Lone Star will implement an active asset
Bureau Veritas appoints Santiago Arias Duval as Executive Vice-President for the Americas region17.11.2025 08:00:00 CET | Press release
Bureau Veritas, a global leader in Testing, Inspection and Certification (TIC), is pleased to announce the appointment of Santiago Arias Duval, effective November 17th, 2025, as Executive Vice-President, Americas. This appointment is in line with Bureau Veritas’ new operating model effective since September 1st, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116192035/en/ Hinda Gharbi, CEO at Bureau Veritas Bureau Veritas is evolving the structure of its executive committee to drive greater organizational alignment. This organization will empower the regions with scalable Product Lines, enabling global solutions development, and will be unlocking wider cross-selling opportunities. The Americas region is created to leverage fast developing market opportunities across countries in North, Central and South America. This is a dynamic region for all Bureau Veritas where the group intends to expand its leadership across p
Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)17.11.2025 07:00:00 CET | Press release
Pending the European Commission decision, Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide will represent an important new therapeutic option from second line for patients with follicular lymphoma (FL) in EuropeIn Western countries, relapsed or refractory FL affects 2-4 out of every 100,000 people1The positive Committee for Medicinal Products for Human Use (CHMP) recommendation is based on data from the Phase 3 inMIND trial which showed patients with relapsed or refractory FL achieved significantly improved progression-free survival with Minjuvi in combination with rituximab and lenalidomide2 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom